Metformin 500 mg twice daily for 12 weeks significantly improved acetylcholine-stimulated endothelial blood flow compared to placebo (p=0.0027) and reduced insulin resistance by 32.5% (p=0.01).
RCT (n=44)
Does metformin improve endothelial function in subjects with diet-treated type 2 diabetes?
Metformin improves both insulin resistance and endothelial function in patients with type 2 diabetes, highlighting the link between insulin sensitivity and vascular health.
p-value: p=0.0027
OBJECTIVES: This study was designed to assess the effect of metformin on impaired endothelial function in type 2 diabetes mellitus. BACKGROUND: Abnormalities in vascular endothelial function are well recognized among patients with type 2 (insulin-resistant) diabetes mellitus. Insulin resistance itself may be central to the pathogenesis of endothelial dysfunction. The effects of metformin, an antidiabetic agent that improves insulin sensitivity, on endothelial function have not been reported. METHODS: Subjects with diet-treated type 2 diabetes but without the confounding collection of cardiovascular risk factors seen in the metabolic syndrome were treated with metformin 500 mg twice daily (n = 29) or placebo (n = 15) for 12 weeks. Before and after treatment, blood flow responses to intraarterial administration of endothelium-dependent (acetylcholine), endothelium-independent (sodium nitroprusside) and nitrate-independent (verapamil) vasodilators were measured using forearm plethysmography. Whole-body insulin resistance was assessed on both occasions using the homeostasis model (HOMA-IR). RESULTS: Subjects who received metformin demonstrated statistically significant improvement in acetylcholine-stimulated flows compared with those treated with placebo (p = 0.0027 by 2-way analysis of variance), whereas no significant effect was seen on nitroprusside-stimulated (p = 0.27) or verapamil-stimulated (p = 0.40) flows. There was a significant improvement in insulin resistance with metformin (32.5% reduction in HOMA-IR, p = 0.01), and by stepwise multivariate analysis insulin resistance was the sole predictor of endothelium-dependent blood flow following treatment (r = -0.659, p = 0.0012). CONCLUSIONS: Metformin treatment improved both insulin resistance and endothelial function, with a strong statistical link between these variables. This supports the concept of the central role of insulin resistance in the pathogenesis of endothelial dysfunction in type 2 diabetes mellitus. This has important implications for the investigation and treatment of vascular disease in patients with type 2 diabetes mellitus.
Mather et al. (2001) conducted an RCT in type 2 diabetes mellitus (n=44). metformin vs. placebo was evaluated on blood flow responses to intraarterial administration of endothelium-dependent (acetylcholine) vasodilators (p=0.0027). Metformin 500 mg twice daily for 12 weeks significantly improved acetylcholine-stimulated endothelial blood flow compared to placebo (p=0.0027) and reduced insulin resistance by 32.5% (p=0.01).